Aim: Immunotherapies blocking the CD47-SIRPα pathway by targeting CD47 enhance macrophage phagocytosis of neoplastic cells in mouse models. As SIRPα exhibits relatively restricted tissue expression, SIRPα antagonists may be better tolerated than agents targeting CD47, which is ubiquitously expressed in many tissues.
receptor on macrophages. CD47 and SIRPα constitute a cell-cell communication system (the CD47-SIRPα system) that is implicated in negative regulation of phagocytosis by macrophages. The intracellular SIRPα region possesses typical immunoreceptor tyrosine-based inhibitory motifs that are phosphorylated after ligation, resulting in cytosolic protein tyrosine phosphatase SHP-1 and/or SHP-2 recruitment and activation. [1] [2] [3] [4] For certain cells (i.e., erythrocytes, platelets, or leukocytes), surface CD47 can protect against macrophagemediated phagocytosis by binding to the inhibitory macrophage receptor SIRPα. [5] [6] [7] The interaction of SIRPα on macrophages with CD47 on leukemia and even solid tumor cells also prevents phagocytosis of such neoplastic cells. Immunotherapies intended to block the CD47-SIRPα pathway have been proven to augment macrophage phagocytosis of several different types of neoplastic cells, primarily in mouse xenogeneic and even syngeneic transplantation models [8] [9] [10] [11] [12] [13] ;
however, their preclinical activities in further clinically relevant models remain to be elucidated.
We have previously shown that the interspecies incompatibility of CD47 is responsible for human macrophage-mediated phagocytosis of xenogeneic porcine cells. Porcine CD47 does not induce SIRPα tyrosine phosphorylation in human macrophages, and porcine cell manipulation for expression of human CD47 markedly reduces their susceptibility to human macrophage-mediated phagocytosis. 14 Beyond such interspecies incompatibility, the non-obese diabetic (NOD) mouse strain provides a better background for human leukocyte and cancer cell engraftment than those of other strains with equivalent immunodeficiency-related mutations owing to the stronger engagement of the SIRPα inhibitory receptor with human CD47, preventing engulfment of human grafts. 15 By using NOD mice with multiple immunodeficient phenotypes, anti-human CD47 monoclonal antibodies (mAbs), as inhibitors of the CD47-SIRPα interaction, have been shown to display anti-tumor activity against various human cancers including leukemia and solid tumors. 9, 13 In these xenograft models, anti-human CD47 mAb targets human CD47 on inoculated human cancer cells but does not recognize mouse CD47 ubiquitously expressed on the host mouse cells. This has raised concerns that effects caused by CD47 binding to multiple other ligands, such as integrins and thrombospondin, which govern a number of processes in normal tissues, might be overlooked. Although examined in mouse models with locally and mainly subcutaneously transplanted syngeneic tumors, [8] [9] [10] [11] [12] [13] this concern remains to be investigated following systemic tumor inoculation. In the present study, we investigated 
| MATERIALS AND METHODS

| Mice
C57BL/6J (B6) mice were purchased from Clea Japan (Osaka, Japan).
CDX2P9.5-NLS Cre and APC LOX/FLOX/FLOX mouse embryos were
obtained from the University of Michigan. These embryos were transferred to pseudopregnant B6 mice, and those carrying the
CDX2P9.5-NLS Cre recombinase transgene and a loxP-treated APC
allele (CPC-APC mice) primarily developed colorectal adenocarcinomas from 9 weeks. 16 
| Cell cultures
The Hepa1-6 B6 murine hepatoma cell line, CMT93 B6 colon cancer cell line and Huh7 human hepatoma cell line were purchased from the American Type Culture Collection (Manassas, VA, USA). Cells were cultured in Dulbecco's modified Eagle's medium (Gibco, NY, USA) containing 10% fetal bovine serum with 5 μmol/L 2-mercaptoethanol (Katayama, Osaka, Japan), 10% HEPES buffer solution (Gibco), and 100 units/mL penicillin and 100 μg/mL streptomycin (Gibco) at 37°Ϲ under a humidified atmosphere of 5% CO 2 in air.
| Anti-SIRPα and anti-CD47 mAbs
Anti-SIRPα mAb was prepared from My-1 hybridoma cells as previously reported. 17 Hybridoma cells were grown in hypoxanthine-aminopterin-thymidine medium supplemented with IL-6, and culture supernatants were screened for Abs reactive to SIRPα-expressing leukocytes by flow cytometry (FCM). Anti-SIRPα mAb was prepared in ascitic fluid from ICR nu/nu mice, determined to be of the IgG type, and purified using protein G-affinity chromatography. 17 Miap301 hybridoma cells producing anti-CD47 mAb were kindly donated by P.
A. Oldenborg (Umeå University, Umeå, Sweden). 7 Anti-CD47 mAb was produced and analyzed in a similar manner as anti-SIRPα mAb.
| Lentiviral-encoded small hairpin RNA (shRNA) knockdown of Hepa1-6 cells
ShRNA constructs targeting knockdown of mouse CD47 or a GFP control were transduced into Hepa1-6 and CMT93 cells as follows.
Cells were seeded into 48-well plates (BD Falcon, San Diego, CA, USA) and incubated at 37°C for 18-20 h in a humidified atmosphere with 5% CO 2 . Hexadimethrine bromide (Sigma-Aldrich, St.
Louis, MO, USA) was then added to each well. An appropriate amount of lentiviral particles at a suitable multiplicity of infection was also added to appropriate wells. Cells were incubated with the viral particle mixture at 37°C overnight. CD47 protein level knockdown was determined by staining with anti-CD47 mAb (clone miap301) with fold knockdown calculated by determining the reduction of mean fluorescence intensity normalized over isotype-control antibody. The following oligonucleotides were used to knockdown CD47 expression: shCD47#1 (CCG GCC CGT TCT GCT ACT TTG ATT TCT CGA GAA ATC AAA GTA GCA GAA CGG GTT TTT G) and shCD47#2 (CCG GCC CGT TCT GCT ACT TTG ATT TCT CGA GAA ATC AAA GTA GCA GAA CGG GTT TTT G). 
| In vivo mAb treatment in CPC-APC mice
| Cell migration assay
A cell migration assay using a Transwell culture system was performed as described previously. 21 Briefly, B6 peritoneal macrophages were labeled with PKH26 using PKH26 Fluorescent Cell Linker Kits 
| Immunofluorescent staining
Cell lines and mouse peritoneal macrophages were stained with PE- 
| Real-time quantitative RT-RCR
RNA was prepared from murine cell lines using RNeasy mini Kit (QIAGEN, Germany). cDNA was prepared from RNA using QuantiTect Reverse Transcription Kit (QIAGEN). CD47 mRNA was measured by real-time quantitative RT-RCR, using the Rotor Gene SYBR Green PCR kit in Rotor Gene Q system (QIAGEN) according to manufacturer's instructions. The primers used in PCR are as follows: 5′
primer (5′-CACAGTCATCGTGGTTGTTGGA-3′) and 3′ primer (5′-GTGATCAATATGGCAATGGTGAAAG-3′) for mouse CD47; 5′ primer (5′-GCGGCATCTTCAAACC-3′) and 3′ primer (5′-TGCCGTGTGAAC-CATG-3′) for β2-Microglobulin (eurofins Genomics) were used as loading control.
| In vitro phagocytosis assay using human reticuloendothelial macrophages
Human reticuloendothelial macrophages were isolated as described previously. 14 In brief, the mononuclear cells were isolated from the perfusion effluents of liver allografts for clinical liver transplantation by gradient centrifugation with Separate-L (Muto Pure Chemicals
Co., Ltd, Tokyo, Japan). To prepare macrophages, cells were plated in a 24-well plate (BD Biosciences) and cultured at 37°Ϲ for 2 h.
Macrophages were used after non-adherent cells were washed away. 
| Statistical analysis
Data are presented as the means ± SD and were analyzed by the Mann-Whitney U-test. Survival curves were generated using the Kaplan-Meier method and compared between different groups by log-rank tests. A P-value of <0.05 was considered statistically significant. All statistical analyses were performed using SPSS software (version 22; IBM Corp., Armonk, NY).
| RESULTS
| Knockdown of CD47 expression increases gastroenterological tumor cell susceptibility to peritoneal macrophage-mediated phagocytosis
To investigate the significance of CD47-SIRPα interactions in macrophage action against gastroenterological tumors, we induced lentiviral-mediated CD47 protein expression knockdown in Hepa1-6 hepatoma and CMT93 colon carcinoma cells originating from B6
mice. FCM analysis revealed that CD47 expression levels in CD47-knockdown (KD) Hepa1-6 cell lines (CD47KD#1 and CD47KD#2
Hepa1-6 cells) were reduced to >70% that of control vector-transfected Hepa1-6 cells (scrambled Hepa1-6 cells) ( Figure 1A ). The CD47 mRNA expression was quantified by using real-time RT-qPCR for demonstrating CD47 knockdown in Hepa1-6 hepatoma cells. As neither Hepa1-6 nor CMT93 cells express surface SIRPα (Figure S2A,B) , anti-SIRPα mAb exclusively targeted peritoneal macrophages in these models. Notably, the similarly administered anti-CD47 mAb did not promote Hepa1-6 and CMT93 cell macrophage phagocytosis in the in vivo phagocytosis assay, and combined anti-SIRPα and anti-CD47 mAb administration by i.p. did not lead to any synergistic macrophage phagocytosis effects ( Figure 3A,B) . Since
IgG2 subclass of anti-CD47 mAb was used in this study, biding anti-CD47 mAb to CD47 on inoculated cancer cells theoretically Macrophage migration through the membrane was significantly inhibited in the presence of anti-CD47 mAb (P = 0.02 at 2 h, P = 0.04 at 8 h vs isotype-control group; P = 0.04 at 2 h, P = 0.02 at 4 h, P = 0.02 at 8 h, P = 0.002 at 16 h vs anti-SIRPα mAb group), whereas anti-SIRPα mAb did not affect transmigration through the membrane, suggesting that signaling through CD47, rather than SIRPα, may be involved in macrophage transmigration/chemotaxis ( Figure 4A,B) . Hence, it is likely that in vivo systemic anti-CD47 mAb administration will lead to less frequent contact with macrophages and tumor cells, limiting its effect on macrophage phagocytosis.
We further evaluated the effects of anti-CD47 and anti-SIRPα mAbs by inoculating Hepa1-6 and CMT93 via the portal vein in B6 mice as a long-term in vivo study. Those cancer cells were not able to be constantly engrafted in untreated syngeneic B6 mice, probably reflecting their vigorous innate immune responses. We found that depletion of NK and NKT cells by using NK1.1 mAb in mice achieved liver metastasis of colorectal cancer cell CMT93 but could not do so with HCC Hepa1-6. In the colorectal liver metastasis model with CMT93, the treatment with anti-SIRPα mAb significantly prolonged the survival of mice inoculated with CMT93, but that with anti-CD47 mAb did not ( Figure 5 ).
| Anti-SIRPα mAb therapy inhibits tumor progression in a sporadic colon cancer mouse model with conditional mutations in APC
To investigate anti-SIRPα mAb therapy inhibitory effects on sporadic solid neoplastic tumor growth, we used a conditional APC knockout CPC-APC mouse model, in which colon-preferential gene targeted mice recapitulate human colorectal cancer. 16 We assessed anti-SIRPα 
| Anti-SIRPα mAb treatment enhances phagocytic activity of human reticuloendothelial macrophages against human hepatoma cells
We carried out an additional study of in vitro phagocytosis assay using human hepatoma cell line (Huh7), and human reticuloendothelial macrophages obtained from liver allograft perfusate collected at liver transplantation, as a further clinically relevant model. Consistent with the results from mouse studies, the treatment with anti-SIRPα mAb significantly enhanced phagocytic activity of human macrophages against human hepatoma cell line, compared with that with isotype-matched control Ab, whereas that with nti-CD47mAb rather reduced (Figure 8 ).
| DISCUSSION
CD47 functions as a phagocytosis inhibitor through ligation of SIRPα expressed on phagocytes, leading to tyrosine phosphatase activation and inhibition of myosin accumulation at the phagocytic synapse submembrane assembly site. 23 CD47 loss leads to homeostatic phagocytosis of aged or damaged cells. 5, 7, 24 We have demonstrated that interspecies CD47 incompatibility in xenotransplantation leads to SIRPα-mediated "don't eat me" signal absence, resulting in the rejection of xenogeneic cells by human macrophages. 14, 20 Whereas macrophages can be activated by pro-phagocytic signaling pathways through activating receptors such as Fcγ and complement receptors, their phagocytic activity is also controlled by immune inhibitory receptor the signal strength. 25 Additionally, lectin-mediated carbohydrate binding may provide activating signals to macrophages without opsonization. 26 We have also demonstrated that a CD47-SIRPα inhibitory signal induced by genomic manipulation overrides such an activating signal delivered to macrophages by xeno-antigens.
Increased cell surface heterophilic carbohydrate antigen expression can be targeted by macrophages, such as Thomsen-Friedenreich antigen (Galß1-3GalNAcα-), a common feature in malignant and premalignant epithelia. 27 Hence, it is likely that CD47-SIRPα signaling may also override the activating signals delivered to macrophages by cancer antigens. Emerging evidence indicates that in various neoplastic cells including solid cancers, CD47 expression is required to avoid innate immune surveillance and elimination by phagocytosis.
Increased CD47 expression has been reported to enable cancer cells to evade macrophage phagocytosis. 8, 9, 11, 12, 28, 29 Here, we demonstrated that the CD47-SIRPα interaction inhibits macrophagemediated phagocytosis, even in gastroenterological tumors.
CD47 is expressed on multiple human tumor types including acute and chronic myeloid leukemia, acute lymphoblastic leukemia, non-Hodgkin's lymphoma, multiple myeloma, bladder cancer, and other solid tumors. [8] [9] [10] 12, 30, 31 Whereas CD47 is ubiquitously expressed at low levels on normal cells, multiple tumors express increased CD47 levels compared to their normal cell counterparts. 10, 29 Although it has been recently demonstrated that hypoxiainducible factor 1 directly activates CD47 gene transcription in hypoxic solid cancer cells, 32 the molecular mechanisms regulating CD47 expression in cancer cells have not been fully determined.
Nevertheless, numerous studies have demonstrated that targeting of CD47 produces noticeable effects on tumor growth inhibition and metastasis prevention of various human cancer types in immunodeficient mouse xenotransplantation models. [9] [10] [11] 33 Recently, studies using syngeneic immunocompetent mouse models have shown that SIRPα is tyrosine phosphorylated and sequestrates SHP2 from IKKß to PI3K regulatory subunit PI3Kp85, resulting in affecting PI3K-Akt and NF-κB pathways in the tumor microenvironment. Therefore, it is likely that administration of anti-CD47 and/or anti-SIRPα mAb interferes Akt and NF-κB activation in macrophages, influencing macrophages migration, survival, cytokines production, and/or angiogenesis in tumor sites. 44 We have demonstrated that anti-SIRPα mAb promotes phagocytic activity of macrophages not only against hepatoma but also against colon carcinoma cells, but anti-CD47 mAb does not.
It remains to be elucidated whether anti-SIRPα mAb causes functional alteration of tumoricidal macrophages or not.
In conclusion, we have demonstrated that anti-SIRPα mAb exhibits enhanced macrophage phagocytic activity and marked anti- 
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